Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Enterprise Value: 2010-2025

Historic Enterprise Value for Catalyst Pharmaceuticals (CPRX) over the last 15 years, with Sep 2025 value amounting to $1.7 billion.

  • Catalyst Pharmaceuticals' Enterprise Value fell 10.22% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.8 million, marking a year-over-year decrease of 102.73%. This contributed to the annual value of $2.0 billion for FY2024, which is 24.91% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Enterprise Value is $1.7 billion, which was down 13.68% from $2.0 billion recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Enterprise Value registered a high of $2.4 billion during Q1 2025, and its lowest value of $335.3 million during Q1 2021.
  • In the last 3 years, Catalyst Pharmaceuticals' Enterprise Value had a median value of $1.6 billion in 2023 and averaged $1.7 billion.
  • Its Enterprise Value has fluctuated over the past 5 years, first spiked by 186.56% in 2022, then fell by 10.22% in 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' Enterprise Value (Quarterly) stood at $506.8 million in 2021, then surged by 140.05% to $1.2 billion in 2022, then grew by 29.73% to $1.6 billion in 2023, then grew by 24.91% to $2.0 billion in 2024, then decreased by 10.22% to $1.7 billion in 2025.
  • Its Enterprise Value was $1.7 billion in Q3 2025, compared to $2.0 billion in Q2 2025 and $2.4 billion in Q1 2025.